Tamoxifen may worsen breast cancer in a small subset of patients. Research published in BioMed Central's open access journal Breast Cancer Research suggests that in patients who show reduced or absent expression of the protein E-cadherin, commonly used anti-oestrogen drugs such as tamoxifen may promote more harmful cancer cell behaviour.
A team of researchers co-ordinated by Dr. Stephen Hiscox, from the Welsh School of Pharmacy at Cardiff University, investigated the selective oestrogen receptor modulator (SERM) tamoxifen on human breast cancer cells, comparing it to the direct effects of oestrogen withdrawal. Dr. Hiscox said, "Anti-oestrogens, such as tamoxifen, have been the mainstay of therapy in patients with oestrogen receptor positive (ER+) breast cancer and have provided significant improvements in survival. Our experimental studies suggest that in a certain group of patients, it may be much less effective, however, as it appear to promote an aggressive cell behaviour".
The authors found that tamoxifen can promote an invasive phenotype in ER+ breast cancer cells under conditions of poor cell-cell contact, a previously unknown effect of this drug. According to Dr. Hiscox, "This could have major clinical implications for those patients with tumours where there is inherently poor intercellular adhesion. In such patients, oestrogen deprivation with aromatase inhibitors (AIs) may be a more appropriate treatment".
E-cadherin is an intercellular adhesion protein important for maintenance of cell-cell adhesion and tissue integrity. The presence of functional oestrogen receptors has been shown to be necessary for its expression.
Notes to Editors
1. Antioestrogens but not oestrogen deprivation promote cellular invasion in intercellular-adhesion deficient breast cancer cells.
Annabel Borley, Stephen Hiscox, Julia Gee, Chris Smith, Victoria Shaw, Peter Barrett-Lee and Robert I Nicholson
Breast Cancer Research (in press)
During embargo, article available here: http://breast-cancer-research.com/imedia/5077764942051606_article.pdf?random=511899
After the embargo, article available at journal website: http://breast-cancer-research.com/
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
Article citation and URL available on request at firstname.lastname@example.org on the day of publication.
2. Breast Cancer Research is an international, peer-reviewed online journal, publishing original research, reviews, commentaries and reports. Research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition, the journal publishes clinical studies with a biological basis, including Phase I and Phase II trials.
3. Cardiff University is recognised in independent government assessments as one of Britain's leading teaching and research universities. It is also ranked as one of the world's top 100 universities by the Times Higher Education (THE). 2008 marks the 125th anniversary of Cardiff University having been founded by Royal Charter in 1883.
Today the University combines impressive modern facilities and a dynamic approach to teaching and research. The University's breadth of expertise in research and research-led teaching encompasses: the humanities; the natural, physical, health, life and social sciences; engineering and technology; preparation for a wide range of professions; and a longstanding commitment to lifelong learning. Cardiff is a member of the Russell Group of the UK's leading research universities. Visit the University website at: www.cardiff.ac.uk
4. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.